Cerebrolysin

What Is Cerebrolysin?

Cerebrolysin is a standardised mixture of low-molecular-weight neuropeptides and amino acids derived from purified porcine brain tissue. Manufactured by EVER Pharma in Austria, it has been in clinical use since the 1970s for neurological conditions including stroke, traumatic brain injury, and Alzheimer's disease.

The peptide fraction (~25% of the solution) contains fragments that mimic the action of endogenous neurotrophic factors:

• Brain-Derived Neurotrophic Factor (BDNF)
• Nerve Growth Factor (NGF)
• Ciliary Neurotrophic Factor (CNTF)
• Insulin-like Growth Factor 1 (IGF-1)

Mechanism of Action

• Neurotrophic factor mimicry -- Cerebrolysin peptides bind to TrkB and p75NTR receptors (same receptors as BDNF/NGF), activating neuronal survival and plasticity pathways
• Neurogenesis promotion -- stimulates differentiation and migration of neural progenitor cells in the hippocampus
• Neuroprotection -- reduces excitotoxicity (glutamate-induced neuronal damage), a primary mechanism of stroke and TBI injury
• Synaptic plasticity -- enhances long-term potentiation (LTP), the cellular basis of learning and memory
• Anti-apoptotic -- activates PI3K/Akt pathway, protecting neurons from programmed cell death

Clinical Evidence Base

Cerebrolysin has over 130 published clinical trials -- an unusually large evidence base for any compound in this category.

A Cochrane-reviewed meta-analysis of stroke trials found significant improvements in global outcome and neurological function in patients receiving Cerebrolysin within 24-72 hours of ischaemic stroke onset.

For Alzheimer's disease, multiple RCTs have shown improvements in the ADAS-cog scale and clinical global impression scores compared to placebo.

Biohacker Use

Outside clinical settings, Cerebrolysin is used in 20-day injection cycles (5ml IM, 5 days/week) for cognitive enhancement, post-concussion recovery, and neurodegenerative disease prevention. This use is extrapolated from therapeutic protocols and lacks direct supporting data.